Discontinued — last reported Q1 '26
U.S. Pharmaceutical — Payments for Restructuring
McKesson U.S. Pharmaceutical — Payments for Restructuring decreased by 50.0% to $2.00M in Q2 2025 compared to the prior quarter. Year-over-year, this metric declined by 33.3%, from $3.00M to $2.00M. Over 3 years (FY 2022 to FY 2025), U.S. Pharmaceutical — Payments for Restructuring shows a downward trend with a -23.7% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
High payments indicate active cash-based restructuring, while lower payments suggest the program is winding down.
Detailed definition
This represents the actual cash outflow related to restructuring activities within the U.S. Pharmaceutical segment durin...
Peer comparison
A standard cash flow component for companies reporting restructuring activities.
mck_segment_u_s_pharmaceutical_payments_for_restructuringHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.00M | $4.00M | $6.00M | $3.00M | $2.00M | $1.00M | $1.00M | $5.00M | $5.00M | $5.00M | $4.00M | $1.00M | $3.00M | $1.00M | $0.00 | $4.00M | $2.00M |
| QoQ Change | — | -20.0% | +50.0% | -50.0% | -33.3% | -50.0% | +0.0% | +400.0% | +0.0% | +0.0% | -20.0% | -75.0% | +200.0% | -66.7% | -100.0% | — | -50.0% |
| YoY Change | — | — | — | — | -60.0% | -75.0% | -83.3% | +66.7% | +150.0% | +400.0% | +300.0% | -80.0% | -40.0% | -80.0% | -100.0% | +300.0% | -33.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's u.s. pharmaceutical — payments for restructuring?
- McKesson (MCK) reported u.s. pharmaceutical — payments for restructuring of $2.00M in Q2 2025.
- How has McKesson's u.s. pharmaceutical — payments for restructuring changed year-over-year?
- McKesson's u.s. pharmaceutical — payments for restructuring decreased by 33.3% year-over-year, from $3.00M to $2.00M.
- What is the long-term trend for McKesson's u.s. pharmaceutical — payments for restructuring?
- Over 3 years (2022 to 2025), McKesson's u.s. pharmaceutical — payments for restructuring has grown at a -23.7% compound annual growth rate (CAGR), from $18.00M to $8.00M.
- What does u.s. pharmaceutical — payments for restructuring mean?
- The actual cash spent on restructuring the U.S. Pharmaceutical business.